Latest news with #STRO
Yahoo
a day ago
- Business
- Yahoo
Applications for Mission Beach whole home short-term rental licenses to reopen
SAN DIEGO (FOX 5/KUSI) — For the first time in nearly three years, San Diego is reopening the application process for short-term vacation rental licenses in one of its most popular beach communities. Starting Tuesday, July 1 at 10 a.m., the City of San Diego will begin accepting Tier 4 Short-Term Residential Occupancy (STRO) license applications for whole-home rentals in Mission Beach. These licenses apply to properties rented out more than 20 days per year in the Mission Beach Community Planning Area. This marks the first opportunity to apply since the city paused Tier 4 applications in November 2022, after quickly reaching capacity during the last application window. Since then, the city has only been processing applicants from a waitlist. The Tier 4 license reopening comes under the framework of the city's STRO Ordinance, adopted by the San Diego City Council and approved by the California Coastal Commission. The rules regulate short-term rentals of fewer than 30 consecutive days, aiming to strike a balance between vacation rentals and long-term housing availability. Cal Fire awards $5.9M in forest health research grants to tackle wildfires 'As a result of this ordinance, we have seen more housing return to the market for San Diego residents, while also providing options for visitors who want to stay in one of San Diego's many vibrant and diverse neighborhoods,' said District 2 Councilmember Jennifer Campbell, whose district includes the beach community. 'Especially in popular areas like Mission Beach, these regulations have protected the neighborhood quality of life, and I am grateful to all the hosts who have adapted to follow this new model for their rentals.' To be eligible, applicants must: Hold an active Transient Occupancy Tax certificate. Be current on all Rental Unit Business Taxes. The application period will remain open for 45 days, ending Aug. 15, 2025. Once closed, the city will conduct a random lottery to determine the processing order and assign waitlist positions, as required by the San Diego's Municipal Code. As explained by the city, existing license holders in lower tiers can apply to be considered for a Tier 4 license. If approved, they'll be required to cancel their current license. San Diego officials confirmed that this reopening does not impact the availability or application process for Tier 1–3 licenses. More information about all license tiers is available online. 'I am committed to continuing to foster a positive and respectful relationship between San Diego residents and visitors as we enter this next phase of licensing,' Campbell continued. For San Diegans and visitors alike, the renewed availability of these licenses could mean more vacation options along the coast — while the city maintains its goal of preserving housing for residents and protecting neighborhood character. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
16-03-2025
- Business
- Yahoo
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Revenue: US$62.0m (down 60% from FY 2023). Net loss: US$227.5m (loss widened by 113% from FY 2023). US$2.96 loss per share (further deteriorated from US$1.78 loss in FY 2023). Phase II: 1. Phase III: 1. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 2.1%. In the last 12 months, the only revenue segment was Development of Biopharmaceutical Products contributing US$62.0m. The largest operating expense was Research & Development (R&D) costs, amounting to US$239.5m (83% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$11.0m. Explore how STRO's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 46% from a week ago. It is worth noting though that we have found 4 warning signs for Sutro Biopharma (1 doesn't sit too well with us!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
